Brooks Laboratories Incorporates Wholly Owned Subsidiary Abridge Speciality Limited

Brooks Laboratories Limited has announced the incorporation of its wholly owned subsidiary, Abridge Speciality Limited, on July 2, 2026. The new entity, with an authorized share capital of ₹1,00,000, will operate in the manufacturing and marketing of pharmaceuticals and related products. This move aligns with the company's strategic objective to expand its business. Abridge Speciality Limited is a related party to Brooks Laboratories Limited, which will hold 100% of its share capital. The subsidiary is yet to commence business operations, hence turnover and net worth are not applicable.